NO20001371D0 - Farmasøytiske preparater inneholdende plasmaprotein - Google Patents

Farmasøytiske preparater inneholdende plasmaprotein

Info

Publication number
NO20001371D0
NO20001371D0 NO20001371A NO20001371A NO20001371D0 NO 20001371 D0 NO20001371 D0 NO 20001371D0 NO 20001371 A NO20001371 A NO 20001371A NO 20001371 A NO20001371 A NO 20001371A NO 20001371 D0 NO20001371 D0 NO 20001371D0
Authority
NO
Norway
Prior art keywords
pharmaceutical preparations
plasma protein
preparations containing
containing plasma
protein
Prior art date
Application number
NO20001371A
Other languages
English (en)
Other versions
NO20001371L (no
NO325294B1 (no
Inventor
Lajos Hegedues
Krisztina Krempels
Krisztina Pasl
Gsbor Petho
Original Assignee
Human Rt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Rt filed Critical Human Rt
Publication of NO20001371D0 publication Critical patent/NO20001371D0/no
Publication of NO20001371L publication Critical patent/NO20001371L/no
Publication of NO325294B1 publication Critical patent/NO325294B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
NO20001371A 1997-09-18 2000-03-16 Vannopploselige organisk losningsmiddel-frie produkter eller farmasoytiske formuleringer, og fremgangsmate for deres fremstilling. NO325294B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701554A HUP9701554D0 (en) 1997-09-18 1997-09-18 Pharmaceutical composition containing plazma proteins
PCT/HU1998/000086 WO1999013914A1 (en) 1997-09-18 1998-09-17 Pharmaceutical compositions containing plasma protein

Publications (3)

Publication Number Publication Date
NO20001371D0 true NO20001371D0 (no) 2000-03-16
NO20001371L NO20001371L (no) 2000-05-18
NO325294B1 NO325294B1 (no) 2008-03-17

Family

ID=90014222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001371A NO325294B1 (no) 1997-09-18 2000-03-16 Vannopploselige organisk losningsmiddel-frie produkter eller farmasoytiske formuleringer, og fremgangsmate for deres fremstilling.

Country Status (33)

Country Link
US (5) US6743826B1 (no)
EP (1) EP0981375B1 (no)
JP (1) JP2001508806A (no)
KR (1) KR100587962B1 (no)
CN (1) CN1189216C (no)
AR (1) AR017120A1 (no)
AT (1) ATE230611T1 (no)
AU (1) AU734695B2 (no)
BG (1) BG64749B1 (no)
BR (1) BR9812469A (no)
CA (1) CA2269923C (no)
CZ (1) CZ301326B6 (no)
DE (1) DE69810612T2 (no)
DK (1) DK0981375T3 (no)
EA (1) EA004700B1 (no)
ES (1) ES2187062T3 (no)
HR (1) HRP980499A2 (no)
HU (1) HUP9701554D0 (no)
IL (1) IL135055A (no)
LT (1) LT4736B (no)
LV (1) LV12493B (no)
NO (1) NO325294B1 (no)
NZ (1) NZ503302A (no)
PL (1) PL193067B1 (no)
PT (1) PT981375E (no)
RO (1) RO118695B1 (no)
RS (1) RS50102B (no)
SI (1) SI20189B (no)
SK (1) SK284683B6 (no)
TR (1) TR200001545T2 (no)
TW (1) TWI222365B (no)
WO (1) WO1999013914A1 (no)
ZA (1) ZA988585B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8137684B2 (en) * 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2000047187A1 (en) * 1999-02-11 2000-08-17 Kinetana Inc. Serum albumin-based parenteral formulations of polyene macrolides
PL202224B1 (pl) 1999-09-16 2009-06-30 Novo Nordisk As Stała kompozycja farmaceutyczna zawierająca związek HSA
AU2001253334A1 (en) * 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
AU2001253336A1 (en) * 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
JP2004529934A (ja) * 2001-05-01 2004-09-30 アンジオテック ファーマシューティカルズ，インコーポレイテッド 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
GR1004274B (el) 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
PL375363A1 (en) 2002-07-16 2005-11-28 Medexis S.A. Steroid conjugates, preparation thereof and the use thereof
AU2003262025A1 (en) * 2002-09-12 2004-04-30 Nihon Medi-Physics Co., Ltd. Preparation for controlling binging of drug to plasma protein
TR200502189T1 (tr) 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
WO2004101620A2 (en) * 2003-05-01 2004-11-25 Compound Therapeutics, Inc. Serum albumin scaffold-based proteins and uses thereof
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
EP1804609A2 (en) * 2004-09-29 2007-07-11 Tel Hashomer Medical Research Infrastructure and Services Ltd. Monitoring of convection enhanced drug delivery
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US8911777B2 (en) 2007-04-04 2014-12-16 Sigmoid Pharma Limited Pharmaceutical composition of tacrolimus
CA2942083C (en) 2007-04-26 2019-01-29 Sigmoid Pharma Limited Manufacture of multiple minicapsules
US20110009497A1 (en) * 2008-03-21 2011-01-13 Fujifilm Corporation Drug-containing composition
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
EP2480208A1 (en) 2009-09-23 2012-08-01 Indu Javeri Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
JP2013515004A (ja) * 2009-12-18 2013-05-02 エクソドス ライフ サイエンシーズ リミテッド パートナーシップ 安定な液体薬剤のための方法および組成物
WO2011097149A2 (en) * 2010-02-03 2011-08-11 Oncbiomune, L.L.C. Taxane-and taxoid-protein compositions
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US10653787B2 (en) 2014-03-18 2020-05-19 Izun Pharmaceuticals Corp Water-based cannabinoid and opioid compositions
KR20170102223A (ko) 2014-11-07 2017-09-08 시그모이드 파마 리미티드 사이클로스포린을 포함하는 조성물
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
JP6983660B2 (ja) * 2015-05-08 2021-12-17 スペクトラル プラットフォームス インコーポレイテッド アルブミンに基づく非共有結合性複合体およびその使用方法
EP3294286A4 (en) 2015-05-15 2019-01-02 Albuvex LLC Docetaxel and human serum albumin complexes
JP2018517736A (ja) * 2015-06-18 2018-07-05 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド 炎症性疾患又は病態を治療する組成物及び方法
US20170128480A1 (en) * 2015-11-09 2017-05-11 Max A. Cayo Cardiac Glycosides for the Treatment of Hypercholesterolemia
EP4019023A1 (en) * 2016-08-03 2022-06-29 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
WO2018081520A1 (en) 2016-10-27 2018-05-03 Zhuhai Beihai Biotech Co., Ltd. Neutral ph compositions of docetaxel and human serum albumin
WO2018175346A1 (en) 2017-03-20 2018-09-27 Spectral Platforms, Inc. Spectroscopic methods to detect and characterize microorganisms
US11744859B2 (en) 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
EP3761960B1 (en) * 2018-03-09 2023-11-22 Kiora Pharmaceuticals GmbH Ophthalmic formulation
EP3811982A1 (en) * 2019-10-25 2021-04-28 Université de Strasbourg Protein-based biomaterial with viscoelastic behaviour, process for obtaining it and uses thereof
CN111529506B (zh) * 2020-05-18 2021-09-03 同济大学 一种两性霉素b白蛋白纳米制剂及其制备方法和应用
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
CN114544926A (zh) * 2021-12-02 2022-05-27 浙江鑫科医疗科技有限公司 一种血清蛋白稳定剂
CN115236216B (zh) * 2022-06-07 2024-03-01 合肥和合医疗科技有限公司 高效液相色谱串联质谱检测全血中免疫抑制剂的试剂盒，其制备方法和检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4833013A (no) * 1971-08-30 1973-05-07
DE2653534C2 (de) * 1975-12-22 1986-08-28 Baxter Travenol Laboratories, Inc., Deerfield, Ill. Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS58216126A (ja) * 1982-06-11 1983-12-15 Ono Pharmaceut Co Ltd 可容化製剤
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
WO1988006457A1 (en) * 1987-03-04 1988-09-07 Nippon Hypox Laboratories Incorporated Medicinal composition containing albumin as carrier and process for its preparation
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5356927A (en) * 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
TR199600775A2 (tr) 1996-09-27 1997-09-21 Tureks Turunc Madencilik Ic Ve Taslara eskitilmis görüntü kazandirilmasi icin bir yöntem.
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Also Published As

Publication number Publication date
ES2187062T3 (es) 2003-05-16
ATE230611T1 (de) 2003-01-15
JP2001508806A (ja) 2001-07-03
EA004700B1 (ru) 2004-06-24
CN1270529A (zh) 2000-10-18
HUP9701554D0 (en) 1997-11-28
CZ2000952A3 (cs) 2000-09-13
AU9362398A (en) 1999-04-05
US8946167B2 (en) 2015-02-03
LT2000018A (en) 2000-08-25
PT981375E (pt) 2003-04-30
ZA988585B (en) 2000-03-13
US7119124B2 (en) 2006-10-10
YU16600A (sh) 2003-08-29
WO1999013914A1 (en) 1999-03-25
EA200000331A1 (ru) 2000-10-30
CN1189216C (zh) 2005-02-16
US20050064028A1 (en) 2005-03-24
SI20189B (sl) 2007-10-31
KR20010052072A (ko) 2001-06-25
NO20001371L (no) 2000-05-18
RS50102B (sr) 2009-01-22
RO118695B1 (ro) 2003-09-30
LT4736B (lt) 2000-12-27
SK3292000A3 (en) 2000-08-14
CZ301326B6 (cs) 2010-01-20
US6743826B1 (en) 2004-06-01
BG64749B1 (bg) 2006-02-28
TR200001545T2 (tr) 2000-10-23
TWI222365B (en) 2004-10-21
BR9812469A (pt) 2002-02-05
DK0981375T3 (da) 2003-05-05
DE69810612D1 (de) 2003-02-13
CA2269923A1 (en) 1999-03-25
BG104245A (en) 2000-11-30
AR017120A1 (es) 2001-08-22
PL339369A1 (en) 2000-12-18
CA2269923C (en) 2003-07-22
AU734695B2 (en) 2001-06-21
US7501455B2 (en) 2009-03-10
NO325294B1 (no) 2008-03-17
LV12493A (en) 2000-06-20
SI20189A (sl) 2000-10-31
LV12493B (en) 2001-01-20
IL135055A0 (en) 2001-05-20
US20070232536A1 (en) 2007-10-04
IL135055A (en) 2004-09-27
EP0981375B1 (en) 2003-01-08
US20100076008A1 (en) 2010-03-25
KR100587962B1 (ko) 2006-06-13
DE69810612T2 (de) 2003-10-02
EP0981375A1 (en) 2000-03-01
PL193067B1 (pl) 2007-01-31
NZ503302A (en) 2001-08-31
US20040014655A1 (en) 2004-01-22
SK284683B6 (sk) 2005-09-08
HRP980499A2 (en) 1999-12-31

Similar Documents

Publication Publication Date Title
DK0981375T3 (da) Farmaceutiske præparater indeholdende plasmaprotein
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
DE69831620D1 (de) Arzneizubereitungen enthaltend Kannabinoide
NO974618D0 (no) Farmasöytiske preparater for intranasal administrasjon
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
ATE200027T1 (de) Tetrahydrolipstatin enthaltende präparate
PL336889A1 (en) Preparations of activated protein c
NO954146D0 (no) Belagte farmasöytiske preparater
DE69625368D1 (de) Schweisshemmende deodorierende präparaten
NO995712D0 (no) Oftalmiske preparater
NO983364D0 (no) Konsensusproteiner
NO980546D0 (no) Farmasöytiske midler
DE69823830D1 (de) Dermatologische zubereitungen
DK0988861T3 (da) Stabiliserede proteinpræparater
DK0925273T3 (da) Farmaceutiske præparater indeholdende 4-oxo-butansyrer
NO994619L (no) Farmasöytiske blandinger
DE69926012D1 (de) Arzneizubereitungen
DK1041966T3 (da) Farmaceutiske præparater omfattende zafirlukast
ATE283706T1 (de) ßGEGEN RACEMISIERUNG STABILISIERTE PHARMAZEUTISCHE ZUBEREITUNGEN VON CILANSETRONß
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
DE69906934D1 (de) Arzneizubereitungen
FI974610A0 (fi) Farmaceutiskt preparat i gelform
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
AUPO495597A0 (en) Raft-forming pharmaceutical preparations
DK0859635T3 (da) Stabiliserede farmaceutiske præparater indeholdende dobutamin

Legal Events

Date Code Title Description
MK1K Patent expired